Study Examines SEROQUEL and the Risk of Cerebrovascular Adverse Events in Elderly Patients With Dementia
Posted on: Saturday, 5 March 2005, 21:00 CST
WILMINGTON, Del., March 5 /PRNewswire-FirstCall/ -- Data presented today at the annual meeting of the American Association of Geriatric Psychiatry (AAGP) include results from a pooled analysis of two 10-week placebo- controlled trials that examined SEROQUEL(R) (quetiapine fumarate) in elderly patients with dementia. The results of a safety analysis, which was performed as a secondary endpoint and assessed the risk of cerebrovascular adverse events (CVAEs) in elderly patients taking SEROQUEL, were presented by Lon S. Schneider, M.D., professor of psychiatry, neurology, and gerontology, at the University of Southern California. These results suggest that SEROQUEL did not increase the risk of CVAEs in this group of patients. CVAEs are a side effect that have been associated with the use of some other atypical antipsychotics in this population.(1A)
"These results are potentially significant for the dementia population, but suggest that quetiapine be further investigated in clinical trials to assess safety and effectiveness," said Lon S. Schneider, M.D., professor of psychiatry, neurology, and gerontology, at the University of Southern California.
Results from the study were initially presented at the 9th International Conference on Alzheimer's Disease and Related Disorders in Philadelphia in July 2004. SEROQUEL is currently approved for the treatment of schizophrenia and the treatment of acute manic episodes associated with bipolar I disorder. SEROQUEL is not approved for treatment of patients with dementia-related psychosis. Since its approval in 1997, SEROQUEL has had over 8 million patient exposures worldwide.
CVAE Analysis
In the results from the safety analysis of CVAEs (mainly stroke and transient ischemic attacks), in the two 10-week, double-blind placebo- controlled trials, a total of 684 patients (mean age 83 years; 80% with Alzheimer's disease, 14% with vascular dementia, and 6% with other dementia types) were randomized to receive SEROQUEL, haloperidol or placebo. The numbers of patients who experienced CVAEs in this pooled data analysis were three in the SEROQUEL (0.8%) group, one in the haloperidol (0.9%) group, and four in the placebo group (1.9%).(1B) The CVAE analysis showed that SEROQUEL was not significantly different than placebo.
IMPORTANT SAFETY INFORMATION ABOUT SEROQUEL
Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia. A rare condition referred to as neuroleptic malignant syndrome has been reported with this class of medications, including SEROQUEL. Patients should be periodically reassessed to determine the need for continued treatment.
Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.
Precautions include the risk of seizures, orthostatic hypotension and cataract development.
The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia and weight gain.
For full prescribing information for SEROQUEL, please visit the website http://www.seroquel.com/.
ABOUT ASTRAZENECA
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States, AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com.
(1) Schneider L, Cerebrovascular Adverse Events and Quetiapine: A Pooled
Analysis in Elderly Patients with Dementia. American Academy for
Geriatric Psychiatry annual meeting, March 2005.
AstraZeneca
CONTACT: Jim Minnick, +1-302-886-5135, jim.minnick@astrazeneca.com, orSandra Heinig, +1-302-885-1084, sandra.heinig@astrazeneca.com, both ofAstraZeneca
Web site: http://www.astrazeneca-us.com/http://www.seroquel.com/
Company News On-Call: http://www.prnewswire.com/comp/985887.html
Source: PRNewswire-FirstCall
Related Articles
- Treatment For Dementia Associated With Risk Of Hospitalization
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance
- Fifth Volume of the Japanese Patient Population Analysis and Epidemiological Survey Now Available
- Japanese Patient Population Analysis Report Provide Nationwide Japanese Patient Population Statistics For All Categories Of Diseases
- Japanese Patient Population Analysis Aims to Provide International Companies and Organizations With Useful Information About the Japanese Healthcare Market
- FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression Treatment
- Debiopharm S.A. Presented Results of a Double-Blind Placebo-Controlled Study on First-in-Class Debio-025 in HIV-1-Infected Subjects
- APhA Foundation Announces Recipients of the Incentive Grants Focused on Serving Patients With Alzheimer's Disease and Dementia
- Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds